fetching data ...

AB0396 (2021)
RAPID IMPROVEMENT IN CYSTOID MACULAR EDEMA WITH HIGH DOSE INTRAVENOUS METHYLPREDNISOLONE IN NON-INFECTIOUS UVEITIS OF DIFFERENT IMMUNE MEDIATED INFLAMMATORY DISEASES
N. Vegas-Revenga1, J. L. Martín-Varillas2, V. Calvo-Río3, I. González-Mazón3, L. Sanchez-Bilbao3, E. Beltrán4, A. Fonollosa5, O. Maiz-Alonso6, A. Blanco7, M. Cordero-Coma8, N. Ortego9, I. Torre-Salaberri10, F. Francisco11, S. Muñoz Fernandez12, M. D. M. Esteban-Ortega13, M. Díaz-Llopis14, J. Cañal15, J. A. Ventosa15, R. Demetrio-Pablo15, L. Domínguez16, M. Agudo-Bilbao3, S. Castañeda17, I. Ferraz-Amaro18, M. A. González-Gay3, R. Blanco3
1Hospital Galdakao-Usansolo, Rheumatology, Galdakao, Spain
2Hospital de Sierrallana, Rheumatology, Sierrallana, Spain
3Hospital Universitario Marqués de Valdecilla, Rheumatology, Santander, Spain
4Hospital Universitario Doctor Peset, Rheumatology, Valencia, Spain
5Hospital Universitario de Cruces, Ophthalmology, Barakaldo, Spain
6Hospital Universitario Donostia, Rheumatology, San Sebastian, Spain
7Hospital Universitario Donostia, Ophthalmology, San Sebastian, Spain
8Hospital de León, Ophthalmology, León, Spain
9Hospital Universitario San Cecilio, Ophthalmology, Granada, Spain
10Hospital Universitario de Basurto, Rheumatology, Bilbao, Spain
11Hospital Universitario de Gran Canaria Doctor Negrín, Rheumatology, Gran Canaria, Spain
12Hospital Universitario Infanta Sofia, Rheumatology, Madrid, Spain
13Hospital Universitario Infanta Sofia, Ophthalmology, Madrid, Spain
14Hospital Universitario La Fe, Ophthalmology, Valencia, Spain
15Hospital Universitario Marqués de Valdecilla, Ophthalmology, Santander, Spain
16Hospital Universitario San Agustín, Rheumatology, Avilés, Spain
17Hospital Universitario de La Princesa, Rheumatology, Madrid, Spain
18Hospital Universitario de Canarias, Rheumatology, Canarias, Spain

Background: Cystoid Macular Edema (CME) is the most important cause of blindness in non-infectious uveitis (NIU) (1). Corticosteroids and conventional and/or biological immunosuppressant may be required (1-6). High-dose intravenous methylprednisolone (IVMP) pulse therapy may induce a rapid improvement.


Objectives: To evaluate the efficacy and safety of IVMP pulse therapy in CME of different immune mediated inflammatory diseases (IMID).


Methods: Multicentre study of 66 patients with severe ocular inflammation who received IVMP. The underlying diseases were: Vogt Koyanagy Harada disease (VKHD)(n=24), Behçet’s disease (BD) (19) and idiopathic NIU (23). The main outcome variable was macular thickness and macular edema (Optical coherence tomography [OCT] >300 μm); that was assessed at 0 (basal), 2-5, 7, 15 and 30 days after IVMP.

The results are expressed as mean ±SD for normally distributed variables, or as median [IQR] when are not. Comparison of continuous variables was performed using the Wilcoxon test.


Results: We studied 43♀/ 23♂ patients. The main features are shown in TABLE 1 . IVMP dose ranged from 250 to 1000 mg/day administered for 3-5 consecutive days, the dose was established according to the presence or not of other systemic manifestations apart from uveitis. All of them had active intraocular inflammation at the moment of the study.

Main features of 66 patients with cystoid macular edema.

VKHD (n=24 ) Idiophatic (n=23 ) Behcet’s disease (n=19 ) Overall (n=66 )
Men/Women, n 5/19 9/14 9/10 66
Mean age (years ) 42 ± 11 47 ± 15 33 ± 10 -
Unilateral/Bilateral, n (% ) 2 (8.3) /22 (91.7 ) 10 (43.5) /13 (56.5) 4 (21) /15 (79) 16/50
Inflammatory ocular patterns, n (% )
 Posterior uveitis 6 (25) 9 (39.1) 3 (15.8) 18
 Panuveitis 18 (75) 14 (60.9) 16 (84.2) 48
Laboratory data, n (% )
 ANA 2 (8.34) 2 (8.7) 0 (0) 4
 HLA B27 0 (0) 4 (17.4) 0 (0) 4
 HLA B29 0 (0) 1 (4.3) 0 (0) 1
 HLA B51 0 (0) 5 (21.7) 8 (42) 13

A rapid and maintained statistically improvement was observed in OCT values in all underlying diseases ( FIGURE 1 ). No major side effects were observed.


Conclusion: High-dose IVMP pulse therapy is useful and safe in the prompt control of CME, regardless of the underlying IMID.


REFERENCES:

[1]Vegas-Revenga N, et al. Am J Ophthalmol. 2019; 200:85-94. doi: 10.1016/j.ajo.2018.12.019.

[2]Calvo-Río V, et al. Clin Exp Rheumatol. 2014;32(4 Suppl 84): S54-7. PMID: 25005576.

[3]Santos-Gómez M, et al. Clin Exp Rheumatol. 2016;34(6 Suppl 102): S34-S40. PMID:27054359.

[4]Atienza-Mateo B, et al. Rheumatology (Oxford) 2018;57(5):856-864. doi: 10.1093/rheumatology/kex480.

[5]Atienza-Mateo B, et al. Arthritis Rheumatol. 2019; 71(12):2081-2089. doi: 10.1002/art.41026.

[6]Martín-Varillas JL, et al. Ophthalmology. 2018;125(9):1444-1451. doi: 10.1016/j.ophtha.2018.02.020.

Improvement of OCT in 66 patients with cystoid macular edema.


Disclosure of Interests: None declared

Citation: Ann Rheum Dis, volume 80, supplement 1, year 2021, page 1225
Session: Vasculitis – small vessel vasculitis (Publication Only)